Association of polypharmacy and burden of comorbidities on COVID-19

adverse outcomes in people with type 1 or type 2 diabetes

- 4 JK Gupta¹, R Ravindrarajah¹, G Tilston¹, W Ollier², DM Ashcroft^{3,4}, AH Heald^{5,6}
- ¹ Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health,
- 6 University of Manchester, Manchester, UK.
- 7 Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK
- ⁸ Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and
- 9 Health, University of Manchester, Manchester, UK.
- ⁴ NIHR Greater Manchester Patient Safety Research Collaboration (PSRC), University of Manchester,
- 11 UK

14

16

18

19

1

2

3

- 12 Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK
- 13 ⁶ Faculty of Biology, Medicine and Health, University of Manchester, UK
- 15 Corresponding author: Adrian.Heald@nca.nhs.uk
- 17 **RUNNING TITLE**: Diabetes and polypharmacy adverse COVID-19 outcome

Abstract

- 20 Aim: To investigate whether polypharmacy and comorbidities conveyed more risk of adverse health
- 21 outcomes following COVID-19 infection in people with type 1 diabetes (T1DM) or type 2 diabetes
- 22 (T2DM).
- 23 Materials and methods: The Greater Manchester Care Record (GMCR) is an integrated database of
- 24 electronic health records containing data collected from 433 general practices in Greater
- 25 Manchester. Baseline demographic information (age, BMI, gender, ethnicity, smoking status,

deprivation index), hospital admission or death within 28 days of infection were extracted for adults (18+) diagnosed with either T1DM or T2DM.

Results: For T2DM, 16 to 20 medications (p=0.005; OR [95% CI]=2.375 [1.306 to 4.319]) and > 20 medications (p<0.001; OR [95% CI]=3.141 [1.755 to 5.621]) were associated with increased risk of death following COVID-19 infection. Increased risk of hospital admissions in T2DM individuals was associated with 11 to 15 medications (p=0.013; OR [95% CI]=1.341 [1.063 to 1.692]) and above. This was independent of comorbidities, metabolic and demographic factors. For T1DM there was no association of polypharmacy with hospital admission. Respiratory, cardiovascular/cerebrovascular and gastrointestinal conditions were associated with increased risk of hospital admissions and deaths in T2DM (p<0.001).

Conclusion: We have shown in T2DM an independent association of multiple medications taken from 11 upwards with adverse health consequences following COVID-19 infection. We also found that individuals with diabetes develop comorbidities that were common across both T1DM and T2DM. This study has laid the foundation for future investigations into the way that complex pharmacological interactions may influence clinical outcomes in people with T2DM.

Keywords: polypharmacy; comorbidity; electronic health records; COVID-19

Introduction

Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 is the pathogenic coronavirus that led to the 2020 pandemic. COVID-19 infections can lead to adverse outcomes, such as hospital admission or death, the risk of which are increased further for individuals diagnosed with either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) ^{1,2}. Increased risk of adverse health outcomes following COVID-19 infection have also been linked to other underlying medical conditions, which has raised concerns for chronic disease care ^{3–7}. It has been showed that socially marginalised and psychiatrically vulnerable individuals are at higher risk of severe health outcomes

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

following COVID-19 infection 8. McQueenie et al. (2020) investigated the UK Biobank data to determine the association between multi-morbidity (including polypharmacy as a proxy) and COVID-19 infection risk 9 . McQueenie et al. (2020) reported that individuals diagnosed with ≥ 2 cardiometabolic conditions and increasing polypharmacy were associated with increased the risk of COVID-19 infection 9. Previous studies of COVID-19 in individuals with T1DM and T2DM (in the Greater Manchester (GM) area) have shown that the prescribing of certain medications influenced the likelihood of hospitalisation or death following COVID-19 infection ^{10,11}. Many individuals in this population are often prescribed, and are taking, multiple medications as they live with other long-term conditions. The definition of 'polypharmacy' has been shown to widely vary in the published literature 12. In addition to this term, Masnoon et al. (2017) summarised that the terms minor, moderate and major polypharmacy were used in literature to describe when between 2 to 11 or more medications are consumed. The most commonly reported number of medications across these 'polypharmacy' terms was greater than or equal to 5, as identified in the review ¹². It is widely accepted that the higher the number of medications prescribed and taken by an individual, the higher the risk of poor health outcomes. Recent reviews have reported a high prevalence of polypharmacy in older people diagnosed with diabetes and an association with several health-related outcomes, including falls, syncope, hospitalization, and death, as well as highlighting the need to reduce inappropriate prescribing ¹³⁻¹⁵. Several studies have also investigated the relationship between polypharmacy and severe COVID-19 health outcomes ^{16,17}. However, there is little understanding of how polypharmacy in people with diabetes might affect their risk of severe health outcome post COVID-19 infection, other than the public health burden and impact of adverse drug-drug interactions in individuals ¹⁸. Electronic health records (EHR) emerged as a useful tool for public health and COVID-19 research, as described by Madhavan et al. (2021) and Casey et al. (2016) 19,20. It is also useful for improving health service for example by identifying and understanding health inequalities ^{21,22}.

ervice for example by identifying and understanding health inequalities .

To date, there are no studies that explore the associations between both polypharmacy and comorbidity with adverse health outcomes, such as hospital admission or death, post first infection of COVID-19 specifically in individuals with diabetes. This retrospective cohort study aimed to investigate whether polypharmacy independent of comorbidity conveys greater risk of adverse outcomes in people with diabetes when testing positive for COVID-19 infection in UK EHR data.

Materials and methods

Cohort data source

The Greater Manchester Care Record (GMCR) is an integrated database of primary care, secondary care and mental health trusts from across GM (https://gmwearebettertogether.com/research-and-planning/) for analyses covering a population of approximately 3 million people. Health and care data were collected from 433 of 435 (99.5%) general practices in GM. Data were de-identified at source and were extracted from the GMCR database. This was a retrospective cohort study with the period of follow-up 2020 to 2022 in relation to the main impact period of the COVID-19 pandemic. The inclusion criteria for this study were defined as individuals that are registered with a GM GP practice and with a diagnosis of T1DM or T2DM and age 18 or above. Individuals with a positive test for COVID-19 close to January 2020 were included in this study. The study included all people diagnosed with diabetes and with data available in the GMCR in January 2020. No power calculation was performed as we included all people with that diagnosis.

Variables and data cleaning

Baseline demographic information (age, BMI, gender, ethnicity, smoking status, deprivation index), hospital admission or death within 28 days of infection were extracted for adults (18+) diagnosed with either T1DM or T2DM (the codes applied are summarised in Appendix 1). Other rare forms of diabetes were not included.

Hospital admissions were recorded within 4 weeks after, or 2 weeks before a positive COVID-19 test (between Jan 2020 to May 2022). The exposure was defined as prescribed medications, which were recorded in the EHRs and mapped to the corresponding BNF (British National Formulary) chapters. For this study, medications were considered at a single point in time, the month closest to first COVID-19 infection date (January 2020 onwards). The BNF groups were not mutually exclusive, therefore medications that are grouped under more than one chapter were counted. History of comorbidity was collected before March 2020.

Individuals who were not assigned a gender were excluded. A total of 410 individuals having a code for both T1DM and T2DM were excluded. The study confounders were determined by literature review. In studies using real world data analysis, a number of factors were not covered in the coded data such as household makeup and employment. Links to the codes used for diabetes can be found in the supplementary information. Data were checked for extreme outliers or inconsistent values and removed as appropriate.

Ethics

This project was reviewed, and ethical approval for COVID-19 research was overseen by Health Innovation Manchester and granted by the Greater Manchester Care Record (GMCR) review board (ref: IDCR-RQ-046). This research was performed with anonymised data, in line with the Health Research Authority's Governance arrangements for research ethics committees.

Statistical methods

Multivariable logistic regression analyses using a forward stepwise approach were performed on the T1DM and T2DM individuals, measuring exposure to number of medications and comorbidities, with either hospital admission or death after COVID-19 infection (within 28 days of COVID-19 diagnosis) as the outcome. The models were adjusted for age, BMI, ethnicity, smoking status, IMD, eGFR <60 ml/min/1.73m², cholesterol, HBA1C and blood pressure. Analyses were performed in STATA v17. This manuscript follows the reporting recommendation of RECORD-PE ²³.

Results

The study cohort included patients diagnosed as T1DM and T2DM separately. Across the Greater Manchester Region a total of 145,907 individuals were diagnosed with T2DM and 9,705 were diagnosed with T1DM (Table 1; Table 2). The number of deaths in T1DM were too low (n=30) for further statistical analyses to explore the association with mortality.

Table 1. Baseline demographics of individual diagnosed with Type 1 diabetes (T1DM) or Type 2 diabetes (T2DM).

	Type 1 Diabetes	Type 2 Diabetes
	N=9,705	N=145,907
Age (years)	47.3±16.8	65.8±13.8
BMI (kg/m²)	27.7±7.0	31.0±7.7
Sex		
Female	4143 (42.7)	65922 (45.2)
Male	5562 (57.3)	79985 (54.8)
Smoking status		
Non-smoker	3967 (40.9)	51823 (35.5)
Current smoker	1804 (18.6)	20906 (14.3)
Ex-smoker	3765 (38.8)	71519 (49.0)
Unknown/missing	169 (1.7)	1659 (1.1)
Ethnicity		
White	8020 (82.6)	102051 (69.9)
Asian	565 (5.8)	25359 (17.4)
Black	221 (2.3)	5176 (3.6)
Mixed	107 (1.1)	1528 (1.1)
Other	379 (3.9)	6184 (4.2)
Missing/refused	413 (4.3)	5609 (3.8)
Deprivation index/Townsend quintile (IMD)		
1 (least deprived)	1182 (12.2)	13471 (9.2)
2	1451 (15.0)	19080 (13.1)
3	1395 (14.4)	18017 (12.4)
4	1984 (20.4)	28863 (19.8)
5 (most deprived)	3680 (37.9)	66426 (45.5)
Missing	13 (0.1)	50 (0.03)
Total number of medications prescribed *		
0	543 (5.60)	13359 (9.16)
1 to 5	5822 (59.99)	51999 (35.64)
6 to 10	1879 (19.36)	38533 (26.41)
11 to 15	744 (7.67)	21433 (14.69)
16 to 20	348 (3.59)	9880 (6.77)
> 20	369 (3.80)	10703 (7.34)
Systolic blood pressure (mm Hg) †	127.1±15.2	131.1±14.5

Diastolic blood pressure (mm Hg) †	74.8±9.8	75.9±9.6
HBA1C (mmol/mol) †	69.3±20.3	56.8±17.0
eGFR (mL/min/1.73 m²) < 60 ‡	907 (9.4)	25851 (17.7)
eGFR (mL/min/1.73 m ²) †	81.0±15.5	75.4±17.2
Cholesterol (mmol/mol) †	4.5±1.1	4.3±1.1
LDL (mmol/L) †	2.4±0.9	2.2±0.9
HDL (mmol/L) †	1.5±0.5	1.2±0.4
Diabetes duration (years)	20.6±14.3	10.4±7.45
Vaccination status: (defined prior to/around the time of first infection)		
Yes	8816 (90.8)	135141 (92.6)
No	889 (9.2)	10766 (7.4)
Prescribed medications: *		
Metformin	1015 (10.5)	72084 (49.4)
SGLT2 °	163 (1.7)	16134 (11.1)
Insulin	6854 (70.6)	12149 (8.3)
Arb/ACE inhibitors	1759 (18.1)	44127 (30.2)
Antiplatelet (clopidogrel/aspirin)	1177 (12.1)	31403 (21.5)
Angiotensin receptor blockers	710 (7.3)	20168 (13.8)
Sulphonylureas	98 (1.0)	22011 (15.1)
GLP1 receptor agonists	79 (0.8)	4475 (3.1)
Alogliptin	36 (0.4)	10196 (7.0)
Linagliptin	37 (0.4)	5388 (3.7)
Saxagliptin	< 10 (0)	944 (0.7)
Sitagliptin	29 (0.3)	6570 (4.5)
Vildagliptin	< 10 (0)	396 (0.27)
Admission to hospital (within 28 days of infection)	146(1.5)	2107 (1.4)
Length of stay in hospital (days)	4.5±8.3	7.1±11.9
Deaths (within 28 days of confirmed infection)	30 (0.3)	885 (0.6)

¹³⁷ Categorical variables presented as N (%) and continuous variables as mean (±SD)

140

143

144

145

146

147

148

149

150

A varying number of multiple medications were prescribed to individuals with T1DM or T2DM (Table 1). A large proportion of individuals were prescribed between 1 to 5 medications; the distribution of number of medications prescribed and BNF chapters can be seen in Figure S1 and Figure S2. In T2DM, after endocrine and cardiovascular medications, the largest number of multiple prescriptions were from the gastrointestinal (GI) BNF chapter.

Common comorbidities were grouped into broader categories (see Supplementary Information

Townsend index: 1 denotes the least deprived and 5 the most deprived.

^{*} Medications prescribed close to January 2020.

[†] Closest point before first COVID-19 +ve test

^{*}Sodium glucose co-transporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist.

identified in T2DM were mental health conditions, hypertension, gastrointestinal or liver disease, pain, respiratory conditions (or sinus-related) and cardiovascular/cerebrovascular conditions (Table 2). Of the individuals diagnosed with T2DM, 69.9% were diagnosed with hypertension and 44.9% with mental health conditions (Table 2). The same six comorbidity groups were also identified in the individuals with T1DM (Table S2).

Table 2. Prevalence of comorbidity groups in individuals diagnosed with T2DM. The top 6 groups are shown in italics.

Morbidity group	N	%
Hypertension	101995	69.9
GI/liver disease	82193	56.3
Mental health disorder	65487	44.9
Pain	60237	41.3
Cardiovascular/cerebrovascular	48213	33.0
Respiratory/sinus	41653	28.6
Sensory	34541	23.7
Skin/connective tissue disorder	28459	19.5
Chronic kidney disease	27931	19.1
Neurological disorders	22795	15.6
Thyroid disorders	14476	9.9
Prostate diseases	9276	6.4
Alcohol substance abuse	9108	6.2
Cancer	7892	5.4
Dementia	6498	4.5
Glaucoma	6262	4.3
Learning disability	1016	0.7

Logistic Regression Analysis

Odds ratios (95% confidence intervals) of the univariate regression are reported in the individuals with T1DM and T2DM respectively.

T1DM

An increased risk of adverse outcomes post-infection was observed for individuals with T1DM and GI/liver disorders (p<0.001; OR [95% CI] = 3.452 [2.118 to 5.625]) and pain associated conditions (p=0.04; OR [95% CI] = 1.556 [1.021 to 2.372]) (Table 3). Age was determined as slightly protective of hospital admission following COVID-19 diagnosis (p<0.001; OR [95% CI] = 0.964 [0.949 to 0.980]).

Other significant variables included eGFR < 60 (p<0.001; OR [95% CI] = 2.794 [1.746 to 4.47]). There was no association with polypharmacy.

Table 3. Logistic regression analyses of hospital admission following COVID-19 diagnosis in individuals with T1DM.

Age 0.964 (0.949 to 0.980) < 0.001	Variable	OR (95% CI)	p value
BMI 0.989 (0.960 to 1.02) 0.485 Ethnicity Asian 0.919 (0.431 to 1.956) 0.826 Black 0.388 (0.052 to 2.882) 0.355 Mixed 1.889 (0.444 to 8.04) 0.390 Other 0.447 (0.108 to 1.852) 0.267 Unknown 0.250 (0.035 to 1.809) 0.170 Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex- smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60 2.794 (1.746 to 4.47) < 0.001 Cholesterol 0.925 (0.780 to 1.097) 0.369 HBA1C 1.002 (0.993 to 1.011) 0.681 Systolic BP 0.998 (0.984 to 1.021) 0.105 Comorbidity groups Mental health disorder	Age	0.964 (0.949 to 0.980)	< 0.001
Ethnicity Asian 0.919 (0.431 to 1.956) 0.826 Black 0.388 (0.052 to 2.882) 0.355 Mixed 1.889 (0.444 to 8.04) 0.390 Other 0.447 (0.108 to 1.852) 0.267 Unknown 0.250 (0.035 to 1.809) 0.170 Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex- smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.655 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Sex	0.792 (0.537 to 1.167)	0.239
Asian 0.919 (0.431 to 1.956) 0.826 Black 0.388 (0.052 to 2.882) 0.355 Mixed 1.889 (0.444 to 8.04) 0.390 Other 0.447 (0.108 to 1.852) 0.267 Unknown 0.250 (0.035 to 1.809) 0.170 Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex- smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	ВМІ	0.989 (0.960 to 1.02)	0.485
Black 0.388 (0.052 to 2.882) 0.355 Mixed 1.889 (0.444 to 8.04) 0.390 Other 0.447 (0.108 to 1.852) 0.267 Unknown 0.250 (0.035 to 1.809) 0.170 Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex- smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Ethnicity		
Mixed 1.889 (0.444 to 8.04) 0.390 Other 0.447 (0.108 to 1.852) 0.267 Unknown 0.250 (0.035 to 1.809) 0.170 Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex-smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60 2.794 (1.746 to 4.47) < 0.001	Asian	0.919 (0.431 to 1.956)	0.826
Other 0.447 (0.108 to 1.852) 0.267 Unknown 0.250 (0.035 to 1.809) 0.170 Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex- smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Black	0.388 (0.052 to 2.882)	0.355
Unknown 0.250 (0.035 to 1.809) 0.170 Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex- smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD Total number of medications 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Mixed	1.889 (0.444 to 8.04)	0.390
Smoking status Current smoker 0.856 (0.487 to 1.507) 0.590 Ex- smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Other	0.447 (0.108 to 1.852)	0.267
Current smoker 0.856 (0.487 to 1.507) 0.590 Ex-smoker 1.022 (0.665 to 1.571) 0.921 Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Unknown	0.250 (0.035 to 1.809)	0.170
Ex-smoker 1.022 (0.665 to 1.571) 0.921	Smoking status		
Unknown/missing 1.237 (0.285 to 5.359) 0.777 IMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Current smoker	0.856 (0.487 to 1.507)	0.590
IMMD 2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Ex- smoker	1.022 (0.665 to 1.571)	0.921
2 0.865 (0.404 to 1.851) 0.708 3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60	Unknown/missing	1.237 (0.285 to 5.359)	0.777
3 0.65 (0.291 to 1.452) 0.294 4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR < 60	IMD		
4 0.999 (0.501 to 1.992) 0.998 5 (most deprived) 0.843 (0.441 to 1.61) 0.604 eGFR<60 2.794 (1.746 to 4.47) < 0.001 Cholesterol 0.925 (0.780 to 1.097) 0.369 HBA1C 1.002 (0.993 to 1.011) 0.681 Systolic BP 0.998 (0.984 to 1.012) 0.788 Diastolic BP 1.018 (0.996 to 1.041) 0.105 Comorbidity groups Mental health disorder 0.690 (0.463 to 1.028) 0.068 Hypertension 1.179 (0.746 to 1.865) 0.480 GI/liver disorder 3.452 (2.118 to 5.625) < 0.001 Pain 1.556 (1.021 to 2.372) 0.040 Respiratory/sinus conditions 0.986 (0.650 to 1.496) 0.948 Cardiovascular/cerebrovascular 1.327 (0.814 to 2.162) 0.257 Total number of medications 1 to 5 1.001 (0.235 to 4.271) 0.999 6 to 10 2.139 (0.488 to 9.381) 0.313 11 to 15 2.496 (0.539 to 11.554) 0.242 16 to 20 3.577 (0.738 to 17.329) 0.113	2	0.865 (0.404 to 1.851)	0.708
5 (most deprived)0.843 (0.441 to 1.61)0.604eGFR<60	3	0.65 (0.291 to 1.452)	0.294
eGFR<602.794 (1.746 to 4.47)< 0.001Cholesterol0.925 (0.780 to 1.097)0.369HBA1C1.002 (0.993 to 1.011)0.681Systolic BP0.998 (0.984 to 1.012)0.788Diastolic BP1.018 (0.996 to 1.041)0.105Comorbidity groupsMental health disorder0.690 (0.463 to 1.028)0.068Hypertension1.179 (0.746 to 1.865)0.480GI/liver disorder3.452 (2.118 to 5.625)< 0.001	4	0.999 (0.501 to 1.992)	0.998
Cholesterol 0.925 (0.780 to 1.097) 0.369 HBA1C 1.002 (0.993 to 1.011) 0.681 Systolic BP 0.998 (0.984 to 1.012) 0.788 Diastolic BP 1.018 (0.996 to 1.041) 0.105 Comorbidity groups Mental health disorder 0.690 (0.463 to 1.028) 0.068 Hypertension 1.179 (0.746 to 1.865) 0.480 Gl/liver disorder 3.452 (2.118 to 5.625) < 0.001	5 (most deprived)	0.843 (0.441 to 1.61)	0.604
HBA1C1.002 (0.993 to 1.011)0.681Systolic BP0.998 (0.984 to 1.012)0.788Diastolic BP1.018 (0.996 to 1.041)0.105Comorbidity groupsMental health disorder0.690 (0.463 to 1.028)0.068Hypertension1.179 (0.746 to 1.865)0.480Gl/liver disorder3.452 (2.118 to 5.625)< 0.001	eGFR<60	2.794 (1.746 to 4.47)	< 0.001
Systolic BP 0.998 (0.984 to 1.012) 0.788 Diastolic BP 1.018 (0.996 to 1.041) 0.105 Comorbidity groups Mental health disorder 0.690 (0.463 to 1.028) 0.068 Hypertension 1.179 (0.746 to 1.865) 0.480 GI/liver disorder 3.452 (2.118 to 5.625) < 0.001	Cholesterol	0.925 (0.780 to 1.097)	0.369
Diastolic BP 1.018 (0.996 to 1.041) 0.105 Comorbidity groups Mental health disorder 0.690 (0.463 to 1.028) 0.068 Hypertension 1.179 (0.746 to 1.865) 0.480 Gl/liver disorder 3.452 (2.118 to 5.625) < 0.001	HBA1C	1.002 (0.993 to 1.011)	0.681
Comorbidity groupsMental health disorder0.690 (0.463 to 1.028)0.068Hypertension1.179 (0.746 to 1.865)0.480GI/liver disorder3.452 (2.118 to 5.625)< 0.001	Systolic BP	0.998 (0.984 to 1.012)	0.788
Mental health disorder0.690 (0.463 to 1.028)0.068Hypertension1.179 (0.746 to 1.865)0.480GI/liver disorder3.452 (2.118 to 5.625)< 0.001	Diastolic BP	1.018 (0.996 to 1.041)	0.105
Hypertension1.179 (0.746 to 1.865)0.480Gl/liver disorder3.452 (2.118 to 5.625)< 0.001	Comorbidity groups		
GI/liver disorder 3.452 (2.118 to 5.625) < 0.001	Mental health disorder	0.690 (0.463 to 1.028)	0.068
Pain 1.556 (1.021 to 2.372) 0.040 Respiratory/sinus conditions 0.986 (0.650 to 1.496) 0.948 Cardiovascular/cerebrovascular 1.327 (0.814 to 2.162) 0.257 Total number of medications 1 to 5 1.001 (0.235 to 4.271) 0.999 6 to 10 2.139 (0.488 to 9.381) 0.313 11 to 15 2.496 (0.539 to 11.554) 0.242 16 to 20 3.577 (0.738 to 17.329) 0.113	Hypertension	1.179 (0.746 to 1.865)	0.480
Respiratory/sinus conditions 0.986 (0.650 to 1.496) 0.948 Cardiovascular/cerebrovascular 1.327 (0.814 to 2.162) 0.257 Total number of medications 1 to 5 1.001 (0.235 to 4.271) 0.999 6 to 10 2.139 (0.488 to 9.381) 0.313 11 to 15 2.496 (0.539 to 11.554) 0.242 16 to 20 3.577 (0.738 to 17.329) 0.113	GI/liver disorder	3.452 (2.118 to 5.625)	< 0.001
Cardiovascular/cerebrovascular1.327 (0.814 to 2.162)0.257Total number of medications1 to 51.001 (0.235 to 4.271)0.9996 to 102.139 (0.488 to 9.381)0.31311 to 152.496 (0.539 to 11.554)0.24216 to 203.577 (0.738 to 17.329)0.113	Pain	1.556 (1.021 to 2.372)	0.040
Total number of medications 1 to 5 1.001 (0.235 to 4.271) 0.999 6 to 10 2.139 (0.488 to 9.381) 0.313 11 to 15 2.496 (0.539 to 11.554) 0.242 16 to 20 3.577 (0.738 to 17.329) 0.113	Respiratory/sinus conditions	0.986 (0.650 to 1.496)	0.948
1 to 5 1.001 (0.235 to 4.271) 0.999 6 to 10 2.139 (0.488 to 9.381) 0.313 11 to 15 2.496 (0.539 to 11.554) 0.242 16 to 20 3.577 (0.738 to 17.329) 0.113	Cardiovascular/cerebrovascular	1.327 (0.814 to 2.162)	0.257
6 to 10 2.139 (0.488 to 9.381) 0.313 11 to 15 2.496 (0.539 to 11.554) 0.242 16 to 20 3.577 (0.738 to 17.329) 0.113	Total number of medications		
11 to 15 2.496 (0.539 to 11.554) 0.242 16 to 20 3.577 (0.738 to 17.329) 0.113	1 to 5	1.001 (0.235 to 4.271)	0.999
16 to 20 3.577 (0.738 to 17.329) 0.113	6 to 10	2.139 (0.488 to 9.381)	0.313
	11 to 15	2.496 (0.539 to 11.554)	0.242
> 20 2.158 (0.424 to 10.989) 0.355	16 to 20	3.577 (0.738 to 17.329)	0.113
	> 20	2.158 (0.424 to 10.989)	0.355

Odds ratios and 95% confidence intervals from the logistic regression model of hospital admission post COVID-19 diagnosis.

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

T2DM In individuals with T2DM, an increased number of medications, from 11 upwards was associated with increased risk of hospital admission following COVID-19 infection (Table 4). Individuals diagnosed with co-morbidities in the following morbidity groups had an increased likelihood of hospital admission: mental health disorders (p=0.003; OR [95% CI] = 1.167 [1.054 to 1.292]); Gastrointestinal/liver disorders (p<0.001; OR [95% CI] = 1.977 [1.741 to 2.245]); pain (p<0.001; OR [95% CI] = 1.407 [1.265 to 1.564]; respiratory/sinus conditions (p<0.001; OR [95% CI] = 1.235 [1.115 to 1.369]) and cardiovascular/cerebrovascular conditions (p<0.001; OR [95% CI] = 1.443 [1.292 to 1.612]). People with T2DM and eGFR level <60 (p<0.001; OR [95% CI] = 1.431 [1.268 to 1.614]) also had an increased risk of hospital admission, similarly HBA1C levels (p=0.009; OR [95% CI] = 1.004 [1.001 to 1.006]) were also at increased risk (Table 4). Males were more likely to be admitted to hospital after infection with COVID-19 (p<0.001; OR [95% CI] = 1.312 [1.181 to 1.457]). High BMI was associated with a higher likelihood of adverse outcomes (hospitalisation & mortality) from COVID-19 (p=0.002; OR [95% CI] = 1.011 [1.004 to 1.018]). Age was protective of hospital admission; however the odds ratio was only slightly less than 1 (p=0.009; OR [95% CI] = 0.993 [0.988 to 0.998]). Individuals of Asian (p=0.006; OR [95% CI] = 1.213 [1.058 to 1.39]) or Black (p=0.003; OR [95% CI] = 1.441 [1.129 to 1.838]) ethnicities were also more likely to be admitted to hospital following infection (Table 4). Individuals who identified as 'current smokers' were not identified as being at increased risk (p<0.001; OR [95% CI] = 0.507 [0.419 to 0.614]). However, individuals who lived in areas with higher social disadvantage were more likely to be admitted to hospital - IMD quintiles 4 and 5 (p=0.02; OR [95% CI] = 1.278 [1.039 to 1.572]; p=0.033; OR [95% CI] = 1.236 [1.017 to 1.503]) (Table 4).

Table 4. Logistic regression analyses of hospital admission within 28 days of COVID-19 diagnosis in individuals with T2DM.

|--|

Age	0.993 (0.988 to 0.998)	0.009
Sex	1.312 (1.181 to 1.457)	< 0.001
BMI	1.011 (1.004 to 1.018)	0.002
Ethnicity		
Asian	1.213 (1.058 to 1.39)	0.006
Black	1.441 (1.129 to 1.838)	0.003
Mixed	1.059 (0.632 to 1.774)	0.827
Other	0.96 (0.744 to 1.239)	0.754
Unknown	0.947 (0.701 to 1.28)	0.725
Smoking status		
Current smoker	0.507 (0.419 to 0.614)	< 0.001
Ex- smoker	0.998 (0.894 to 1.115)	0.977
Unknown/missing	0.856 (0.525 to 1.396)	0.533
IMD		
2	1.07 (0.851 to 1.345)	0.562
3	1.091 (0.868 to 1.373)	0.454
4	1.278 (1.039 to 1.572)	0.020
5 (most deprived)	1.236 (1.017 to 1.503)	0.033
eGFR<60	1.431 (1.268 to 1.614)	< 0.001
Cholesterol	1.021 (0.976 to 1.068)	0.369
HBA1C	1.004 (1.001 to 1.006)	0.009
Systolic BP	1.001 (0.997 to 1.005)	0.709
Diastolic BP	1.002 (0.996 to 1.008)	0.470
Comorbidity groups		
Mental health disorder	1.167 (1.054 to 1.292)	0.003
Hypertension	1.074 (0.946 to 1.219)	0.272
GI/liver disorder	1.977 (1.741 to 2.245)	< 0.001
Pain	1.407 (1.265 to 1.564)	< 0.001
Respiratory/sinus conditions	1.235 (1.115 to 1.369)	< 0.001
Cardiovascular/cerebrovascular	1.443 (1.292 to 1.612)	< 0.001
Total number of medications		
1 to 5	1.123 (0.901 to 1.401)	0.302
6 to 10	1.108 (0.886 to 1.387)	0.370
11 to 15	1.341 (1.063 to 1.692)	0.013
16 to 20	1.45 (1.124 to 1.87)	0.004
> 20	1.53 (1.191 to 1.966)	0.001

Odds ratios and 95% confidence intervals from the logistic regression model of hospital admission post COVID-19 diagnosis.

In individuals with T2DM, the number of deaths was 885 (0.6% of the total number of individuals diagnosed with T2DM) (Table 1). An increased number of medications, from 16 to 20 to > 20 was associated with increased risk of death following COVID-19 infection (p=0.005; OR [95% CI] = 2.375 [1.306 to 4.319] and p<0.001; OR [95% CI] = 3.141 [1.755 to 5.621] respectively) (Table 5).

People diagnosed with the following long-term conditions were at higher risk of death post-infection: mental health disorders (p<0.001; OR [95% CI] = 1.544 [1.219 to 1.954]); respiratory/sinus conditions (p<0.001; OR [95% CI] = 1.573 [1.245 to 1.988]) or cardiovascular/cerebrovascular conditions (p<0.001; OR [95% CI] = 1.691 [1.297 to 2.203]). A protective effect was observed for individuals living with GI/liver disorder (p<0.001; OR [95% CI] = 0.519 [0.404 to 0.666]) or pain (p<0.001; OR [95% CI] = 0.513 [0.4 to 0.657]) (Table 5).

As with hospital admission, the risk of death increased in males and with high BMI (p=0.017; OR [95% CI] = 1.35 [1.054 to 1.728] and p=0.004; OR [95% CI] = 1.021 [1.007 to 1.036] respectively). Age was associated with an increased risk of mortality post COVID-19 infection (p<0.001; OR [95% CI] = 1.092 [1.078 to 1.107]) (Table 5).

Individuals with T2DM and living in the most deprived regions (IMD 5) were at higher risk of death following COVID-19 infection (p=0.021; OR [95% CI] = 1.684 [1.081 to 2.623]) or if their eGFR level measure was <60 (p=0.011; OR [95% CI] = 1.382 [1.078 to 1.771]) (Table 5).

Table 5. Logistic regression analyses of deaths within 28 days of COVID-19 diagnosis in individuals with T2DM.

Variable	OR (95% CI)	p value
Age	1.092 (1.078 to 1.107)	< 0.001
Sex	1.35 (1.054 to 1.728)	0.017
вмі	1.021 (1.007 to 1.036)	0.004
Ethnicity		
Asian	0.719 (0.46 to 1.123)	0.147
Black	0.666 (0.272 to 1.631)	0.374
Mixed	1.418 (0.447 to 4.5)	0.553
Other	0.696 (0.357 to 1.36)	0.289
Smoking status		
Unknown	1.259 (0.717 to 2.212)	0.423
Current smoker	1.015 (0.665 to 1.549)	0.945
Ex- smoker	0.945 (0.724 to 1.234)	0.677
Unknown/missing	Omitted	
IMD		
2	1.444 (0.88 to 2.37)	0.146
3	1.181 (0.7 to 1.993)	0.534
4	1.481 (0.921 to 2.381)	0.105
5 (most deprived)	1.684 (1.081 to 2.623)	0.021
eGFR<60	1.382 (1.078 to 1.771)	0.011

Cholesterol	1.084 (0.973 to 1.207)	0.145
HBA1C	1 (0.992 to 1.008)	0.967
Systolic BP	0.993 (0.985 to 1.002)	0.122
Diastolic BP	1.001 (0.987 to 1.015)	0.906
Comorbidity groups		
Mental health disorder	1.544 (1.219 to 1.954)	< 0.001
Hypertension	0.794 (0.574 to 1.099)	0.164
GI/liver disorder	0.519 (0.404 to 0.666)	< 0.001
Pain	0.513 (0.4 to 0.657)	< 0.001
Respiratory/sinus conditions	1.573 (1.245 to 1.988)	< 0.001
Cardiovascular/cerebrovascular	1.691 (1.297 to 2.203)	< 0.001
Total number of medications		
1 to 5	0.583 (0.32 to 1.06)	0.077
6 to 10	0.945 (0.536 to 1.665)	0.844
11 to 15	1.429 (0.802 to 2.545)	0.226
16 to 20	2.375 (1.306 to 4.319)	0.005
> 20	3.141 (1.755 to 5.621)	< 0.001

Odds ratios and 95% confidence intervals from the logistic regression model of mortality post COVID-19 diagnosis.

Discussion

This study uniquely explored the relationship between number of medications and adverse outcome from COVID-19 infection in individuals diagnosed with diabetes in the Greater Manchester population and is therefore distinct from our previous published studies in this area ^{10,11}. We found that the number of medications prescribed to an individual was associated with an increased risk of severe outcome from COVID-19 infection, particularly in people living with T2DM (Table 4; Table 5). Given the large proportion of individuals diagnosed with comorbidities, it was not unexpected that many of these individuals were prescribed multiple medications (Figure S1; Figure S2). However, the effect of multiple medications was independent of the presence of the most common comorbidities. Polypharmacy, independent of other factors including major multimorbidity, was associated with an increased likelihood of hospital admission in people with T1DM and of hospitalisation and death in T2DM following COVID-19 infection. This has not been specifically reported previously, although it was described in older individuals ²⁴. This is of relevance to the consequences following any serious viral infection in people with diabetes, while also highlighting the importance of regular medicine

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

reviews in everyone with diabetes, where there may be an opportunity to reduce the prescribed medications 25. The mean ages of individuals diagnosed with T1DM or T2DM are similar to the mean ages of a Swedish cohort investigated by 1. In our study we also identified several co-morbidities that increased the risk of adverse health outcome post COVID-19 infection. Similar co-morbidities were identified for both individuals with T1DM and T2DM. Notably, we also identified that there were a large proportion of diagnoses of mental health conditions in people with T2DM (Table 2), though the highest number of diagnoses was observed in people with T1DM (Table S2). The relation between physical health conditions and poor mental health is an area that is not fully understood. In addition to this, the impact of polypharmacy is unknown. The risk of hospital admission in current smokers was less than non-smokers. The reason for this may be that people with multiple health issues and who are smokers may have stopped smoking in the weeks or months before a COVID-19 infection and therefore not be deemed as a smoker at the time of the COVID-19 infection. Over-prescribing is an issue in the current healthcare system. Medication is routinely recorded, therefore in clinical practice there is the potential to flag the number of medications prescribed to clinicians to monitor. Thereby the number of prescriptions given to vulnerable individuals could be limited as appropriate and effective for the individual, though this does require both routine monitoring and structured reviews of the medications that people are taking. The UK healthcare system looks to improve the management of prescriptions, and the removal of unnecessary medications is key to reducing the burden of polypharmacy ^{26,27}. One of the limitations of this study is that a measure of 'frailty' was not included 28. However, a count of comorbidities is included which could possibly be used as a proxy for frailty. As the data from this study originated from electronic health records, it is also subject to the limitations of how information is coded when originally entered into the systems, such as missing data. Only 70% of individuals with T1DM were recorded with a prescription of insulin (Table 1), this could be due to

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

lack of recording or unclear diagnosis, which highlights another issue with routinely collected data. Another issue is that medications are recorded in the health care records are not true reflections of medications that are concordant with the choices of the individual ²⁹. A study in the United States demonstrated that EHR-related medication errors can occur at different stages including at ordering, preparation, dispensing, administering or monitoring stage, these can ultimately affect the data in EHRs ³⁰. Inaccuracies of coding are inherent in any project that relies on primary coded data. Nevertheless, the large number of people included in the study means that such inaccuracies are unlikely materially to influence the results. Furthermore, medications can also be counted in more than one BNF chapter, making it difficult to determine unique counts. As this data was from one region in the UK, it is difficult to generalise to the rest of the population. Finally in studies using real world data analysis, there will be a number of factors that are not covered in the coded data such as household makeup and employment. Future work would include investigating the modal medications prescribed in this cohort and explore possible drug-drug interactions between medications that could contribute to increasing the risk of adverse outcome post COVID-19 infection. The burden of mental health conditions on people with diabetes and how to effectively manage multiple long-term conditions, could also be explored. The knowledge gained would be useful for future pandemics and better prepare our healthcare system. In conclusion, we have identified that multiple medications were prescribed to many people living with diabetes and that this was associated with a higher risk of adverse health outcome following COVID-19 infection. We also found that individuals with diabetes also developed comorbidities that were common across both Type 1 and 2 diabetes. Our analysis confirmed the impact of higher levels of deprivation on increasing a person's a risk of adverse outcome post COVID-19 infection. This study has laid the foundation for future investigations into the increased and complex treatments people living with diabetes who develop other clinical complications.

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

Acknowledgements This work was supported by the Turing-Manchester Feasibility Project Funding. The authors recognise the Greater Manchester Care Record (a partnership of Greater Manchester Health and Social Care Partnership, Health Innovation Manchester and Graphnet Health, on behalf of Greater Manchester localities) in the provision of data required to undertake this work. This work uses data provided by patients and collected by the NHS as part of their care and support. GT was funded by the NIHR Manchester Biomedical Research Centre (NIHR203308) for this work. DMA is supported by the NIHR Greater Manchester Patient Safety Research Collaboration (PSRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. **Author contributions** RR performed the data cleaning and data analyses. JG, WO and AHH conceived the study. JG prepared the figures and the manuscript. GT extracted the original dataset. DM WO and AHH contributed to all sections of the paper and DM provided expert input from a pharmacological perspective. All authors were involved in designing the study, interpreting results and the reviewing and editing of the manuscript. Conflicts of interest Authors declare no conflict of interest. Data availability statement The datasets generated during and analysed during the current study are not publicly available as all data access is subject to review by Health Innovation Manchester. Supplementary Materials Links to the clinical codes applied for diabetes diagnoses can be found in the 'methods' section of the supplementary material file. Figure S1: distribution of medications prescribed in T1DM

316 individuals. Figure S2: distribution of medications prescribed in T1DM individuals. Table S1: 317 breakdown of comorbidity groups. Table S2: Prevalence of comorbidities groups in T1DM. **Preprint** 318 319 A preprint has previously been published [31]. References 320 321 Rawshani A, Kjölhede EA, Rawshani A, et al. Severe COVID-19 in people with type 1 and type 2 322 diabetes in Sweden: A nationwide retrospective cohort study. The Lancet Regional Health -323 Europe. 2021;4:100105. doi:10.1016/j.lanepe.2021.100105 324 Izzi-Engbeaya C, Distaso W, Amin A, et al. Adverse outcomes in COVID-19 and diabetes: a 325 retrospective cohort study from three London teaching hospitals. BMJ Open Diabetes Res Care. 326 2021;9(1):e001858. doi:10.1136/bmjdrc-2020-001858 327 Kone AP, Martin L, Scharf D, et al. The impact of multimorbidity on severe COVID-19 outcomes 328 in community and congregate settings. Dialogues in Health. 2023;2:100128. 329 doi:10.1016/j.dialog.2023.100128 330 Li Y, Ashcroft T, Chung A, et al. Risk factors for poor outcomes in hospitalised COVID-19 patients: 331 A systematic review and meta-analysis. J Glob Health. 11:10001. doi:10.7189/jogh.11.10001 332 5. Fekadu G, Bekele F, Tolossa T, et al. Impact of COVID-19 pandemic on chronic diseases care 333 follow-up and current perspectives in low resource settings: a narrative review. Int J Physiol 334 Pathophysiol Pharmacol. 2021;13(3):86-93. 335 Danhieux K, Buffel V, Pairon A, et al. The impact of COVID-19 on chronic care according to 336 providers: a qualitative study among primary care practices in Belgium. BMC Family Practice. 337 2020;21(1):255. doi:10.1186/s12875-020-01326-3 338 Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic 339 literature review and meta-analysis. Journal of Infection. 2020;81(2):e16-e25. 340 doi:10.1016/j.jinf.2020.04.021 341 8. Nilsson SF, Laursen TM, Osler M, et al. Adverse SARS-CoV-2-associated outcomes among people 342 experiencing social marginalisation and psychiatric vulnerability: A population-based cohort 343 study among 4,4 million people. The Lancet Regional Health - Europe. 2022;20:100421. 344 doi:10.1016/j.lanepe.2022.100421 345 McQueenie R, Foster HME, Jani BD, et al. Multimorbidity, polypharmacy, and COVID-19 infection 346 within the UK Biobank cohort. PLOS ONE. 2020;15(8):e0238091. 347 doi:10.1371/journal.pone.0238091 348 10. Heald AH, Jenkins DA, Williams R, et al. The Risk Factors Potentially Influencing Hospital 349 Admission in People with Diabetes, Following SARS-CoV-2 Infection: A Population-Level Analysis.

Diabetes Ther. 2022;13(5):1007-1021. doi:10.1007/s13300-022-01230-2

350

351 11. Heald AH, Jenkins DA, Williams R, et al. Mortality in People with Type 2 Diabetes Following 352 SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. Diabetes Ther. 353 2022;13(5):1037-1051. doi:10.1007/s13300-022-01259-3 354 12. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review 355 of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2 356 13. Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy 357 in older patients with type 2 diabetes. Aging Clin Exp Res. 2022;34(9):1969-1983. 358 doi:10.1007/s40520-022-02165-1 359 14. Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and 360 deprescribing in older people: through a sex and gender lens. The Lancet Healthy Longevity. 361 2021;2(5):e290-e300. doi:10.1016/S2666-7568(21)00054-4 362 15. Bhagavathula AS, Vidyasagar K, Chhabra M, et al. Prevalence of Polypharmacy, 363 Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A 364 Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2021;12. Accessed August 11, 365 2023. https://www.frontiersin.org/articles/10.3389/fphar.2021.685518 366 16. McKeigue PM, Kennedy S, Weir A, et al. Relation of severe COVID-19 to polypharmacy and 367 prescribing of psychotropic drugs: the REACT-SCOT case-control study. BMC Medicine. 368 2021;19(1):51. doi:10.1186/s12916-021-01907-8 369 17. Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: A systematic review. J 370 Am Pharm Assoc (2003). 2021;61(5):e14-e25. doi:10.1016/j.japh.2021.05.006 371 18. Rahman S, Singh K, Dhingra S, et al. The Double Burden of the COVID-19 Pandemic and 372 Polypharmacy on Geriatric Population – Public Health Implications. Ther Clin Risk Manag. 373 2020;16:1007-1022. doi:10.2147/TCRM.S272908 374 19. Madhavan S, Bastarache L, Brown JS, et al. Use of electronic health records to support a public 375 health response to the COVID-19 pandemic in the United States: a perspective from 15 376 academic medical centers. J Am Med Inform Assoc. 2021;28(2):393-401. 377 doi:10.1093/jamia/ocaa287 378 20. Casey JA, Schwartz BS, Stewart WF, Adler NE. Using Electronic Health Records for Population 379 Health Research: A Review of Methods and Applications. Annual Review of Public Health. 380 2016;37(1):61-81. doi:10.1146/annurev-publhealth-032315-021353 381 21. Kruse CS, Stein A, Thomas H, Kaur H. The use of Electronic Health Records to Support Population 382 Health: A Systematic Review of the Literature. J Med Syst. 2018;42(11):214. 383 doi:10.1007/s10916-018-1075-6 384 22. Cowie MR, Blomster JI, Curtis LH, et al. Electronic health records to facilitate clinical research. 385 Clin Res Cardiol. 2017;106(1):1-9. doi:10.1007/s00392-016-1025-6

23. Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). *BMJ*. Published online November 14, 2018:k3532. doi:10.1136/bmj.k3532

386

387

388

389 24. Rahman S, Singh K, Dhingra S, et al. The Double Burden of the COVID-19 Pandemic and 390 Polypharmacy on Geriatric Population – Public Health Implications. Ther Clin Risk Manag. 391 2020;16:1007-1022. doi:10.2147/TCRM.S272908 392 25. Kerr L. Polypharmacy in diabetes and solutions for greater adherence. *Practical Diabetes* 393 International. 2009;26(7):289-290i. doi:10.1002/pdi.1402 394 26. The ASHN Network. Polypharmacy. The AHSN Network. Published 2022. Accessed April 7, 2023. 395 https://www.ahsnnetwork.com/programmes/medicines/polypharmacy/ 396 27. Department of Health and Social Care. National overprescribing review report. GOV.UK. 397 Published 2023. Accessed April 7, 2023. https://www.gov.uk/government/publications/national-398 overprescribing-review-report 399 28. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged 400 and older adults and its association with multimorbidity and mortality: a prospective analysis of 401 493 737 UK Biobank participants. The Lancet Public Health. 2018;3(7):e323-e332. 402 doi:10.1016/S2468-2667(18)30091-4 403 29. Marzec LN, Maddox TM. Medication Adherence in Patients with Diabetes and Dyslipidemia: 404 Associated Factors and Strategies for Improvement. Curr Cardiol Rep. 2013;15(11):418. 405 doi:10.1007/s11886-013-0418-7 406 30. Carayon P, Du S, Brown R, Cartmill R, Johnson M, Wetterneck TB. EHR-related medication errors 407 in two ICUs, J Healthc Risk Manag. 2017;36(3):6-15. doi:10.1002/jhrm.21259 408 31. Gupta JK, Ravindrarajah R, Tilston G, Ollier W, Ashcroft DM, Heald AH. (2023). Association of 409 polypharmacy and burden of comorbidities on COVID-19 adverse outcomes in people with type 1 or 410 type 2 diabetes. MedRxiv. https://www.medrxiv.org/content/10.1101/2023.08.12.23294016v1.full 411